Detalles de la búsqueda
1.
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
Breast Cancer Res
; 13(1): R17, 2011 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21294885
2.
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells.
Sci Rep
; 11(1): 2231, 2021 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33500516
3.
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Int J Oncol
; 59(1)2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34013359
4.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Cancer Immunol Immunother
; 59(9): 1295-312, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20532501
5.
Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction.
Eur J Med Chem
; 203: 112574, 2020 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683167
6.
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
Leukemia
; 34(5): 1315-1328, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836849
7.
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Theranostics
; 9(22): 6706-6718, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31588245
8.
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy.
Clin Cancer Res
; 25(15): 4775-4790, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31061069
9.
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
J Immunother Cancer
; 7(1): 29, 2019 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30717773
10.
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Gynecol Oncol
; 108(1): 141-8, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17988723
11.
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Clin Cancer Res
; 13(11): 3356-62, 2007 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17545543
12.
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
J Nucl Med
; 59(8): 1234-1242, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674421
13.
Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.
Sci Rep
; 7(1): 14918, 2017 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29097747
14.
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
Oncotarget
; 8(59): 99950-99965, 2017 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29245952
15.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Oncotarget
; 8(23): 37061-37079, 2017 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28427157
16.
Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
Oncotarget
; 8(13): 22034-22047, 2017 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28423546
17.
Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects.
Antioxid Redox Signal
; 25(8): 467-84, 2016 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27224059
18.
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.
Biochem J
; 379(Pt 3): 785-93, 2004 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14750901
19.
Introduction to radiobiology of targeted radionuclide therapy.
Front Med (Lausanne)
; 2: 12, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25853132
20.
Peptides derived from the two regulatory domains of p53 are recognized by two p53-activating antibodies.
Peptides
; 24(3): 339-45, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12732330